References
1. Geoghegan S., Erviti A., Caballero M.T., Vallone F., Zanone S.M., Losada J.V., Bianchi A., Acosta P.L., Talarico L.B., Ferretti A., Grimaldi L.A., Sancilio A., Dueñas K., Sastre G., Rodriguez A., Ferrero F., Barboza E., Gago G.F., Nocito C., Flamenco E., Perez A. R., Rebec B., Ferolla F.M., Libster R., Karron R.A., Bergel E., Polack F.P. Mortality due to respiratory syncytial virus. Burden and risk factors. Am J Respir Crit Care Med. 2017; 195 (1): 96–103. DOI: https://doi.org/10.1164/rccm.201603-0658OC
2. Langedijk A.C., Bont L.J. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023; 21 (11): 734–49. DOI: https://doi.org/10.1038/s41579-023-00919-w
3. Currie S.M., Findlay E.G., McFarlane A.J., Fitch P.M., Böttcher B., Colegrave N., Paras A., Jozwik A., Chiu C., Schwarze J., Davidson D.J. Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J Immunol. 2016; 196 (6): 2699–710. DOI: https://doi.org/10.4049/jimmunol.1502478
4. Mulder K.C.L., Lima L.A., Miranda V.J., Dias S.C., Franco O.L. Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides. Front Microbiol. 2013; 4: 321. DOI: https://doi.org/10.3389/fmicb.2013.00321
5. Wegzyn C., Toh L.K., Notario G., Biguenet S., Unnebrink K., Park C., Makari D., Norton M. Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther. 2014; 3 (2): 133–58. DOI: https://doi.org/10.1007/s40121-014-0046-6
6. Aravinda S., Shamala N., Roy R.S., Balaram P. Non-protein amino acids in peptide design. J Chem Sci. 2003; 115: 373–400. DOI: https://doi.org/10.1007/BF02708230
7. Khaitov M.R., Nikonova A.A., Shilovskiy I.P., Kozhikhova K.V., Kofiadi I.A., Gudima G.O., Vishnyakova L.I., Nikolskii A.A., Kovchina V.I., Timotievich E.D., Yumashev K.V., Smirnov V.V., Maerle A.V., Kozlov I.B., Shatilov A.A., Shatilova A.V., Andreev S.M., Koloskova O.O., Kuznetsova N.A., Vasina D.V., Nikiforova M.A., Rybalkin S.P., Sergeev I.V., Trofimov D.Y., Martynov A.I., Berzin I.A., Gushchin V.A., Kovalchuk A.V., Borisevich S.V., Skvortsova V.I. MIR 19® – world first specific antiviral drug for COVID-19 treatment. Development and preclinical studies. Immunologiya. 2023; 44 (3): 270–90. DOI: https://doi.org/10.33029/0206-4952-2023-44-3-270-290 (in Russian)
8. Khaitov M.R., Nikonova A.A., Kofi adi I.A., Shilovsky I.P., Smirnov V.V., Elisyutina O.G., Gudima G.O., Maerle A.V., Shatilov A.A., Shatilova A.V., Andreev S.M., Sergeev I.V., Trofimov D.Yu., Latysheva T.V., Ilyina N.I., Martynov A.I., Rabdano S.O., Ruzanova E.A., Savelyev N.S., Pletyukhina Yu.V., Safi A.S., Ratnikov V.A., Gorelov V.P., Kashchenko V.A., Kucherenko N.G., Umarova I.A., Moskaleva S.S., Fabrichnikov S.V., Zuev O.V., Pavlov N.B., Kryuchko D.S., Berzin I.A., Goryachev D.V., Merkulov V.A., Shipulin G.A., Yudin S.M., Trukhin V.P., Valenta R., Skvortsova V.I. Results of clinical trials phases I and II of MIR 19®. Immunologiya. 2023; 44 (3): 291–316. DOI: https://doi.org/10.33029/1816-2134-2023-44-3-291-316 (in Russian)
9. Sinclair J.F., O’Brien A.D. Intimin types α, β, and γ bind to nucleolin with equivalent affinity but lower avidity than to the translocated intimin receptor. J Biol Chem. 2004; 279 (32): 33751–8. DOI: https://doi.org/10.1074/jbc.M401616200
10. Song N., Ding Y., Zhuo W., He T., Fu Z., Chen Y., Song X., Fu Y., Luo Y. The nuclear translocation of endostatin is mediated by its receptor nucleolin in endothelial cells. Angiogenesis. 2012; 15 (4): 697–711. DOI: https://doi.org/10.1007/s10456-012-9284-y
11. Watanabe T., Hirano K., Takahashi, A. Yamaguchi K., Beppu M., Fujiki H., Suganuma M. Nucleolin on the cell surface as a new molecular target for gastric cancer treatment. Biol Pharm Bull. 2010; 33 (5): 796–803. DOI: https://doi.org/10.1248/bpb.33.796
12. Gautier R., Douguet D., Antonny B., Drin G. HELIQUEST: a web server to screen sequences with specific α-helical properties. Bioinformatics. 2008; 24 (18): 2101–2. DOI: https://doi.org/10.1093/bioinformatics/btn392
13. Kozhikhova K.V., Shilovskiy I.P., Shatilov A.A., Timofeeva A.V., Turetskiy E.A., Vishniakova L.I., Nikolskii A.A., Barvinskaya E.D., Karthikeyan S., Smirnov V.V., Kudlay D.A., Andreev S.M., Khaitov M.R. Linear and dendrimeric antiviral peptides: Design, chemical synthesis and activity against human respiratory syncytial virus. J Mat Chem B. 2020; 13 (8): 2607–17. DOI: https://doi.org/10.1039/C9TB02485A
14. Kozhikhova K.V., Andreev S.M., Uspenskaya D.V., Shatilova A.V., Turetsky E.A., Shatilov A.A., Lushnikova A.A., Vishnyakova L.I., Shilovskiy I.P., Smirnov V.V., Kudlay D.A., Khaitov M.R. Supercationic peptide dendrimers as vectors for nucleic acids delivery to mammalian cells. Immunologiya. 2022; 43 (3): 320–32. DOI: https://doi.org/10.33029/0206-4952-2022-43-3-320-332 (in Russian)
15. Shatilov A.A., Shatilova A.V., Mislavskij O.V., Cherchenko N.G., Saprygina L.V., Babihina M.O., Smirnov V.V., Khaitov M.R. Evaluation of the effectiveness of use of polycationic dendrimer peptides as covalent adjuvants for recombinant birch pollen allergen rBet v 1. Cardiovascular therapy and prevention. 2023; 22S6: 102–3. DOI: https://doi.org/10.15829/1728-8800-2023-6S (in Russian)
16. Sommer P., Fluxa V.S., Darbre T., Reymond J. Proteolysis of peptide dendrimers. Chembiochem. 2009; 10 (9): 1527–36. DOI: https://doi.org/10.1002/cbic.200900060